Abstract
The Urticaria Activity Score and its summed score over 7 days (UAS7) are the validated guideline-recommended reference standards for disease activity for adults with chronic spontaneous urticaria (CSU).1 However, the UAS7 remains to be validated in children. The Children’s Dermatology Life Quality Index (CDLQI) is a questionnaire used to estimate quality of life2 and has been validated for use in chronic urticaria for ages 4 years and older.3 We aimed to validate the use of UAS7 in children presenting with CSU through assessment of correlation with the CDLQI score, through the assessment of the effect of increased antihistamine dose on UAS7, and through evaluation of the association between high UAS7 in children and the need for omalizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Allergy and Clinical Immunology: In Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
